Alnylam Pharmaceuticals
ALNY
#786
Rank
C$44.83 B
Marketcap
C$335.07
Share price
-2.42%
Change (1 day)
-46.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$5.27

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$5.30. In 2025 the company made an earnings per share (EPS) of C$2.52.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$5.27109.35%
2025C$2.52
2023C-$4.94-62%
2022C-$12.9929.03%
2021C-$10.07-3.36%
2020C-$10.42-8.48%
2019C-$11.397.67%
2018C-$10.5739.74%
2017C-$7.5712.94%
2016C-$6.7038.84%
2015C-$4.83-32.88%
2014C-$7.19259.44%
2013C-$2.00-31.25%
2012C-$2.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.82 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$3.58-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$59.49 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$0.80-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.02-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.38-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.92-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$1.13-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA